Burmakin et al 2024 Supplementary Information

A therapeutic A1M protein variant (RMC-035) is currently in Phase 2 clinical development for renal protection in patients undergoing open chest cardiac surgery. It targets several key pathways underlying kidney injury in this patient group, including oxidative stress, heme-toxicity, and mitochondrial dysfunction. RMC-035 is rapidly eliminated from plasma, distributing to kidney proximal tubules, and demonstrates dose-dependent efficacy in numerous models of ischemia-reperfusion injury, particularly when administered before ischemia. These results support its continued clinical evaluation.